

## JULY

Date	Headline and Source	Link	Summary
1 <sup>st</sup> July	CDSCO Panel Approves Novartis Protocol Amendment Proposal To Study Ruxolitinib and Panobinostat Medical Dialogues, July 01, 2024	<a href="#">CDSCO Panel Approves Novartis Protocol Amendment Proposal To Study Ruxolitinib and Panobinostat</a>	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol amendment proposal presented by the drug major Novartis for the clinical trial protocol titled "Open Label, Multi-Center, Phase IV Study of Ruxolitinib or Ruxolitinib and Panobinostat Combination, for Patients Who Have Completed Prior Global Novartis or Incyte Sponsored Studies".
2 <sup>nd</sup> July	Budget 2024: Pharma industry seeks better incentives to increase investments in R&D, grow market size to \$120-\$130 bn Live Mint, July 02, 2024	<a href="#">Budget 2024: Pharma industry seeks better incentives to increase investments in R&amp;D, grow market size to \$120-\$130 bn</a>	Industry body Organisation of Pharmaceutical Producers of India (OPPI), which represents various global research-based pharma firms in India, is optimistic about continued reforms in policies aimed at bolstering innovation in the industry and streamlining its regulatory processes.
2 <sup>nd</sup> July	OPPI urges government to boost R&D and innovation in pharma sector ahead of Union Budget Express Pharma, July 02, 2024	<a href="#">OPPI urges government to boost R&amp;D and innovation in pharma sector ahead of Union Budget</a>	In anticipation of the upcoming Union budget, the Organisation of Pharmaceutical Producers of India (OPPI) has voiced its expectations and recommendations for the healthcare and pharma sector. Anil Matai, Director General of OPPI, expressed optimism about the government's ongoing efforts to enhance quality healthcare and the continuous reforms aimed at bolstering innovation and streamlining regulatory processes.
2 <sup>nd</sup> July	Indian Pharma Industry demands better incentives in upcoming Budget 2024 Janta Se Rishta, July 02, 2024	<a href="#">Indian Pharma Industry demands better incentives in upcoming Budget 2024</a>	Given the high-risk, long-term nature of R&D, we suggest extending the scope of section 115BAB of the Income Tax Act, 1961 to companies engaged only in pharmaceutical R&D and providing a deduction rate of 200% on R&D expenditure, said Anil Matai, Director General, OPPI.
2 <sup>nd</sup> July	CDSCO Panel Approves AstraZeneca pharma's Protocol Amendment proposal to study Anifrolumab Medical Dialogues, July 02, 2024	<a href="#">CDSCO Panel Approves AstraZeneca pharma's Protocol Amendment proposal to study Anifrolumab</a>	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has approved the drug major AstraZeneca Pharma India's protocol amendment proposal to study anifrolumab.

2 <sup>nd</sup> July	Sightsavers India and AbbVie India host consultation on glaucoma awareness India Whispers, July 02, 2024	<a href="#">Sightsavers India and AbbVie India host consultation on glaucoma awareness</a>	Sightsavers India, in collaboration with AbbVie India, successfully launched a series of statelevel consultations across India to raise awareness about the prevention of visual impairment due to glaucoma. The inaugural event took place at Lemon Tree Premier in Bhubaneswar, Odisha, drawing a diverse audience that included ophthalmologists, senior optometrists, public health professionals, civil society representatives, social scientists, and journalists.
3 <sup>rd</sup> July	Zydus Cadila in Association with Japan s Takeda Pharma to Develop Chikungunya Vaccine Silicon India, July 03, 2024	<a href="#">Zydus Cadila in Association with Japan s Takeda Pharma to Develop Chikungunya Vaccine</a>	Zydus Cadila joins hand with Japan's Takeda Pharmaceutical to prepare vaccine that will provide immunity against chikungunya. The contract between the companies includes developing the vaccine from the scratch till the final commercialization of the vaccine.
3 <sup>rd</sup> July	Novo Nordisk Gets CDSCO Panel Nod To Import, Market Insulin Icodec to treat diabetes mellitus in adults Medical Dialogues, July 03, 2024	<a href="#">Novo Nordisk Gets CDSCO Panel Nod To Import, Market Insulin Icodec to treat diabetes mellitus in adults</a>	This came after the firm presented the product approval from the NRA of the country of origin, i.e., the EMA for grant of permission to import and market Insulin Icodec 700 U/ml, 1050 U/1.5 ml, and 2100 U/3 ml. Insulin icodec is a once-weekly basal insulin analogue designed to cover the basal insulin requirements for a full week with a single subcutaneous injection.
4 <sup>th</sup> July	Eli Lilly Company Gets CDSCO Panel Nod To Import, Market Antidiabetic drug Tirzepatide for chronic weight management Medical Dialogues, July 04, 2024	<a href="#">Eli Lilly Company Gets CDSCO Panel Nod To Import, Market Antidiabetic drug Tirzepatide for chronic weight management</a>	The drug major Eli Lilly Company India has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to import and market antidiabetic medication Tirzepatide 2.5mg/0.5ml, 5mg/0.5ml, 7.5mg/0.5ml, 10mg/0.5ml, 12.5mg/0.5ml, and 15mg/0.5ml solutions for injection in a single-dose prefilled pen and in a single-dose vial for chronic weight management.
5 <sup>th</sup> July	AstraZeneca to invest Rs 250 crore in expanding its GITC in Chennai Business Standard, July 05, 2024	<a href="#">AstraZeneca to invest Rs 250 crore in expanding its GITC in Chennai</a>	AstraZeneca India (AZIPL), the global capability centre (GCC) of the pharma major AstraZeneca, said on Thursday that the company will invest Rs 250 crore in expanding its Global Innovation and Technology Centre (GITC) in Chennai.
6 <sup>th</sup> July	Union Budget 2024-25 wish list: Expectations from health, pharma sector Business Today, July 06, 2024	<a href="#">Union Budget 2024-25 wish list: Expectations from health, pharma sector</a>	We commend the government's efforts to enhance quality healthcare and are optimistic about the continued reforms and policies aimed at bolstering innovation and streamlining regulatory

			processes, said Anil Matai, Director General of the Organisation of Pharmaceutical Producers of India (OPPI).
6 <sup>th</sup> July	Novo Nordisk Gets CDSCO Panel Nod to Study Cagrilintide plus semaglutide Medical Dialogues, July 06, 2024	<a href="#">Novo Nordisk Gets CDSCO Panel Nod to Study Cagrilintide plus semaglutide</a>	New Delhi: The drug major Novo Nordisk has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct a phase II clinical study of the antidiabetic drug combination cagrilintide plus semaglutide.
6 <sup>th</sup> July	AstraZeneca plans to invest Rs 250 crore to grow its Global Innovation and Technology Centre in India, bringing some 1,300 highly skilled roles by 2025 Express Pharma, July 06, 2024	<a href="#">AstraZeneca plans to invest Rs 250 crore to grow its Global Innovation and Technology Centre in India, bringing some 1,300 highly skilled roles by 2025</a>	AstraZeneca plans to invest Rs 250 crore to grow its Global Innovation and Technology Centre in India, bringing some 1,300 highly skilled roles by 2025 AstraZeneca India (AZIPL), the Global Capability Centre (GCC) of AstraZeneca, announced an investment of 250 crore rupees (\$30 million) to expand its Global Innovation and Technology Centre (GITC) in Chennai, Tamil Nadu, which includes close to 1,300 roles focused on driving innovation, enhancing efficiency, and streamlining operations across the company globally.
7 <sup>th</sup> July	AstraZeneca Pharma India gets CDSCO Panel Nod to study anticancer drug Datopotamab deruxtecan/Rilvegostomig Medical Dialogues, July 07, 2024	<a href="#">AstraZeneca Pharma India gets CDSCO Panel Nod to study anticancer drug Datopotamab deruxtecan/Rilvegostomig</a>	The drug major AstraZeneca Pharma India has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the phase 3 clinical study of the anticancer drug Datopotamab deruxtecan (DS1062a) 100mg/ vial Rilvegostomig (AZD2936) 750 mg/vial (50 mg/ml).
8 <sup>th</sup> July	Budget 2024: Pharma sector seeks tax sops, effective intellectual property rights regime The Economic Times, July 08, 2024	<a href="#">Budget 2024: Pharma sector seeks tax sops, effective intellectual property rights regime</a>	Outlining the sector's wish list for the upcoming Union Budget, Organisation of Pharmaceutical Producers of India (OPPI) Director General Anil Matai urged the government to explore methods to incentivise R&D investments, such as deductions on R&D expenses, research-linked incentives for MNCs, and corporate tax concessions.
9 <sup>th</sup> July	Budget 2024: Pharma sector seeks tax sops, effective intellectual property rights regime ET Health World, July 09, 2024	<a href="#">Budget 2024: Pharma sector seeks tax sops, effective intellectual property rights regime</a>	Outlining the sector's wish list for the upcoming Union Budget, Organisation of Pharmaceutical Producers of India (OPPI) Director General Anil Matai urged the government to explore methods to incentivise R&D investments, such as deductions on R&D expenses, research

			linked incentives for MNCs, and corporate tax concessions.
9 <sup>th</sup> July	Sanofi Healthcare Gets CDSCO Panel Nod to Import and Market Belumosudil Tablets Medical Dialogues, July 09, 2024	<a href="#">Sanofi Healthcare Gets CDSCO Panel Nod to Import and Market Belumosudil Tablets</a>	Noting an unmet medical need, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to the drug major Sanofi Healthcare to import and market Belumosudil tablets 200 mg, with a condition to conduct a Phase IV clinical trial (CT) study involving high-volume transplant centers (more than 100) across the country.
10 <sup>th</sup> July	Tax Benefits, Intellectual Property Rights On Pharma Industry's Budget Wishlist NDTV, July 10, 2024	<a href="#">Tax Benefits, Intellectual Property Rights On Pharma Industry's Budget Wishlist</a>	Outlining the sector's wish list for the upcoming Union Budget, Organisation of Pharmaceutical Producers of India (OPPI) Director General Anil Matai urged the government to explore methods to incentivise R&D investments, such as deductions on R&D expenses, research-linked incentives for MNCs, and corporate tax concessions.
11 <sup>th</sup> July	This company is launching a device that helps diabetics sleep better using AI Hindustan Times, July 11, 2024	<a href="#">This company is launching a device that helps diabetics sleep better using AI</a>	Swiss pharmaceutical giant Roche said that it will soon launch a device that uses artificial intelligence to predict possible low blood sugar events during the night. This will help those with diabetes to sleep without worry as diabetics can have episodes of low blood sugar levels hypoglycaemia during the night that are likely to disrupt their sleep, sometimes even requiring medical intervention.
12 <sup>th</sup> July	SIIC IIT-K partners with Boehringer Ingelheim India to support dementia care innovation The Times of India, July 12, 2024	<a href="#">SIIC IIT-K partners with Boehringer Ingelheim India to support dementia care innovation</a>	The Startup Incubation and Innovation Centre (SIIC) at the Indian Institute of Technology Kanpur on Thursday signed an MoU with Boehringer Ingelheim India, a leading global pharmaceutical company, to advance solutions in the field of dementia care.
13 <sup>th</sup> July	Budget 2024: Healthcare and pharma sectors push for reforms and incentives CNBC TV18, July 13, 2024	<a href="#">Budget 2024: Healthcare and pharma sectors push for reforms and incentives</a>	Anil Matai, Director General, the Organisation of Pharmaceutical Producers of India (OPPI) echoed similar sentiments To accelerate R&D and innovation, we urge the government to explore methods to incentivise R&D investments, such as deductions on R&D expenses, research-linked incentives for MNCs, and corporate tax concessions.
13 <sup>th</sup> July	Roche Products India gets CDSCO Panel Nod To study anticancer drug Pralsetinib	<a href="#">Roche Products India gets CDSCO Panel Nod To study</a>	The drug major Roche Products India has got approval from the Subject Expert Committee (SEC) functional under the

	Capsule Medical Dialogues, July 13, 2024	<a href="#">anticancer drug Pralsetinib Capsule</a>	Central Drug Standard Control Organisation (CDSCO) to conduct the phase III clinical study of the anticancer drug Pralsetinib Capsules 100mg.
13 <sup>th</sup> July	Pfizer and Amrita Hospital unveil a COE for adult vaccination Express Healthcare, July 13, 2024	<a href="#">Pfizer and Amrita Hospital unveil a COE for adult vaccination</a>	Pfizer India and Amrita Hospital, Faridabad, have collaborated to unveil a new dedicated Centre of Excellence (CoE) for adult vaccination in Amrita Hospital, Faridabad. The COE has been set up to promote holistic communitywide adult vaccination coverage against several vaccine preventable diseases (VPDs), including Pneumococcal disease, Influenza, Human papillomavirus (HPV), and Hepatitis A and B, among others.
13 <sup>th</sup> July	SIIC IIT Kanpur, Boehringer Ingelheim collaborate to develop a tele-neurorehabilitation app Express Healthcare, July 13, 2024	<a href="#">SIIC IIT Kanpur, Boehringer Ingelheim collaborate to develop a tele-neurorehabilitation app</a>	The Boehringer Ingelheim India team, comprising Gagandeep Singh Bedi, Managing Director, and, Prabhat Sinha, Director of Government and Public Affairs, Corporate Affairs, visited SIIC, IIT Kanpur, to strengthen their partnership in fostering healthcare innovations. The MoU was exchanged between Ankush Sharma, Professor-in-Charge, SIIC, IIT Kanpur, and Gagandeep Singh Bedi, MD Boehringer Ingelheim India.
14 <sup>th</sup> July	Merck completes acquisition of Eye Bio Medical Dialogues, July 14, 2024	<a href="#">Merck completes acquisition of Eye Bio</a>	Additional pipeline candidates include clinical and preclinical assets being developed for the prevention and treatment of vision loss associated with retinal vascular leakage, a known risk factor for retinal diseases. Read also: Merck Captative gets USFDA nod for prevention of Invasive Pneumococcal Disease, Pneumococcal Pneumonia in adults
14 <sup>th</sup> July	Zydus Cadila in Association with Japan s Takeda Pharma to Develop Chikungunya Vaccine Silicon India, July 14, 2024	<a href="#">Zydus Cadila in Association with Japan s Takeda Pharma to Develop Chikungunya Vaccine</a>	The contract between the companies includes developing the vaccine from the scratch till the final commercialization of the vaccine. The chikungunya virus is transmitted by Aedes aegypti and Aedes albopictus mosquitoes to humans, same species of mosquitoes that spread dengue and zika.
15 <sup>th</sup> July	Pfizer Moves Forward With Once-Daily Weight-Loss Pill Dd News Gov, July 15, 2024	<a href="#">Pfizer Moves Forward With Once-Daily Weight-Loss Pill</a>	The new drug is part of the second generation of weight loss pills under development by companies including Eli Lilly and Novo Nordisk that will offer patients a more convenient alternative to injections. Some analysts expect the weight loss drug market, currently

			dominated by Novo Nordisk's Wegovy and Eli Lilly's Zepbound, to be worth more than \$150 billion in annual sales by the early 2030s.
15 <sup>th</sup> July	CDSCO Panel approves Novartis Healthcare for selective use of Eculizumab dose up to 300 mg Medical Dialogues, July 15, 2024	<a href="#">CDSCO Panel approves Novartis Healthcare for selective use of Eculizumab dose up to 300 mg</a>	Reviewing the justification presented by the drug major Novartis Healthcare for the monoclonal antibody Eculizumab, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has opined the firm to use the dose up to 300 mg only in patients who continue to have active psoriatic arthritis and active ankylosing spondylitis in line with USFDA Approved prescribing information (PI).
15 <sup>th</sup> July	Tamil Nadu emerges as GCC magnet, pharma major AstraZeneca leads the charge Business Standard, July 15, 2024	<a href="#">Tamil Nadu emerges as GCC magnet, pharma major AstraZeneca leads the charge</a>	Earlier this month, British Swedish pharmaceutical (pharma) major AstraZeneca announced the expansion of its global capability center (GCC) in Chennai, marking it as the company's largest such center worldwide. This development underscores Tamil Nadu's emergence as India's latest hotspot for GCCs, with over 50,000 jobs created by more than 40 global companies in the past three years.
15 <sup>th</sup> July	CDSCO Panel Approves Johnson and Johnson's Protocol Amendment Proposal to study anticancer drug Amivantamab Medical Dialogues, July 15, 2024	<a href="#">CDSCO Panel Approves Johnson and Johnson's Protocol Amendment Proposal to study anticancer drug Amivantamab</a>	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has approved the drug major Johnson and Johnson's protocol amendment proposal to study the anticancer drug Amivantamab (JNJ61186372) with the condition that an interim analysis report before the LTE (longterm extension) phase shall be submitted to CDSCO.
15 <sup>th</sup> July	Boehringer Ingelheim India ties up with SIIC, IITK for healthcare innovation Medical Buyer, July 15, 2024	<a href="#">Boehringer Ingelheim India ties up with SIIC, IITK for healthcare innovation</a>	The Startup Incubation and Innovation Centre (SIIC), the technology business incubator of the Indian Institute of Technology Kanpur (IITK), has entered into an agreement with Boehringer Ingelheim India. The Boehringer Ingelheim India team, consisting of Gagandeep Singh Bedi, Managing Director, and Prabhat Sinha, Director of Government and Public Affairs.
15 <sup>th</sup> July	Zydus Cadila in Association with Japan's Takeda Pharma to Develop Chikungunya Vaccine Silicon India, July 15, 2024	<a href="#">Zydus Cadila in Association with Japan's Takeda Pharma to Develop Chikungunya Vaccine</a>	Presently, there are no specific vaccines for chikungunya. This partnership between Cadila and Takeda Pharmaceutical is all set to improve access to medicine soon. It has been reported that since 2005,

			chikungunya virus has affected over 1.9 million people across India, Indonesia, Maldives, Myanmar and Thailand.
15 <sup>th</sup> July	TN emerges as GCC magnet, AstraZeneca leads the charge Business Standard, July 15, 2024	<a href="#">TN emerges as GCC magnet, AstraZeneca leads the charge</a>	Tamil Nadu's emergence as India's latest hotspot for GCCs, with over 50,000 jobs created by more than 40 global companies in the past three years, intensifying competition in the region. AstraZeneca joins Pfizer and Roche, who have also established their centers in the state. Global giants such as World Bank Group (the largest outside its headquarters).
16 <sup>th</sup> July	Zydus Cadila in Association with Japan s Takeda Pharma to Develop Chikungunya Vaccine Silicon India, July 16, 2024	<a href="#">Zydus Cadila in Association with Japan s Takeda Pharma to Develop Chikungunya Vaccine</a>	Zydus Cadila joins hand with Japan's Takeda Pharmaceutical to prepare vaccine that will provide immunity against chikungunya. The contract between the companies includes developing the vaccine from the scratch till the final commercialization of the vaccine.
17 <sup>th</sup> July	Mankind Pharma inks pact with Takeda to commercialise acidity drug in India Business Standard, July 17, 2024	<a href="#">Mankind Pharma inks pact with Takeda to commercialise acidity drug in India</a>	Delhi-based Mankind Pharma Limited has signed a nonexclusive patent licence agreement with Takeda Pharmaceuticals for commercialising acidity drug Vonoprazan in the Indian market. The agreement allows Mankind Pharma to launch the novel drug for treating Gastroesophageal Reflux Disease (GERD) under its trademark, the company said in a statement.
17 <sup>th</sup> July	Boehringer Ingelheim India enters into second collaboration with SIIC IIT Kanpur to support healthcare innovation The Week, July 17, 2024	<a href="#">Boehringer Ingelheim India enters into second collaboration with SIIC IIT Kanpur to support healthcare innovation</a>	Boehringer Ingelheim India is providing a grant to Manastik Technologies incubated at Startup Incubation and Innovation Centre (SIIC). Manastik Technologies is developing India's first tele neurorehabilitation app a one stop solution for dementia patients and caregivers considering the problems and challenges faced by the community.
17 <sup>th</sup> July	Mankind, Takeda Ink Licensing Pact to Sell Acidity Drug The Economic Times, July 17, 2024	<a href="#">Mankind, Takeda Ink Licensing Pact to Sell Acidity Drug</a>	The Delhi-based company has entered into in-licensing agreements with Novartis for heart failure therapy Neptaz. In May 2024, it signed a licensing agreement with AstraZeneca to distribute inhaled corticosteroid drug Symbicort in India.
18 <sup>th</sup> July	Budget 2024 Expectations Highlights: Union Budget should focus on tax reforms, employment generation, says FICCI Economic Outlook Survey The Financial Express, July 18, 2024	<a href="#">Budget 2024 Expectations Highlights: Union Budget should focus on tax reforms, employment generation, says FICCI Economic Outlook Survey</a>	Budget 2024 Income Tax Slab Highlights: In another five days, the much-anticipated Union Budget 2024-25 will be presented in the Lok Sabha by Union Finance and Corporate Minister Nirmala Sitharaman on July 23. Anil Matai, Director General of the Organisation of Pharmaceutical Producers

			of India (OPPI), expressed appreciation for the government's efforts to enhance healthcare quality in India. He highlighted optimism about ongoing reforms aimed at fostering innovation and streamlining regulatory processes.
18 <sup>th</sup> July	Boehringer Ingelheim India, IITK partner for healthcare innovation Medical Buyer, July 18, 2024	<a href="#">Boehringer Ingelheim India, IITK partner for healthcare innovation</a>	The Startup Incubation and Innovation Centre (SIIC), the technology business incubator of the Indian Institute of Technology Kanpur (IITK), has entered into an agreement with Boehringer Ingelheim India. The Boehringer Ingelheim India team, consisting of Gagandeep Singh Bedi, Managing Director, and Prabhat Sinha, Director of Government and Public Affairs, Corporate Affairs, visited SIIC, IITK to strengthen their partnership for fostering healthcare innovations.
18 <sup>th</sup> July	Sanofi looking to expand India hub with Rs 3.6kcr push The Economic Times, July 18, 2024	<a href="#">Sanofi looking to expand India hub with Rs 3.6kcr push</a>	French drugmaker Sanofi plans to invest 400 million (about 3,600 crore) over the next six years to expand its global capability centre (GCC) in Hyderabad by increasing the headcount and further developing the facility. Of the total, 100 million will be invested by the end of 2025.
18 <sup>th</sup> July	Zydus ties with Takeda to sell GERD drug Live Mint, July 18, 2024	<a href="#">Zydus ties with Takeda to sell GERD drug</a>	Ahmedabad based Zydus Lifesciences Limited has entered into a nonexclusive patent licensing agreement with Takeda Pharmaceutical Company to market the novel Potassium Competitive Acid Blocker (PCAB) Vonoprazan in India for the treatment of gastroesophageal reflux disease (GERD), it said in a statement on 17 July, Wednesday.
19 <sup>th</sup> July	Budget 2024 Expectations: Need to introduce policies to provide direct and indirect tax benefits for R&D and investments The Financial Express, July 19, 2024	<a href="#">Budget 2024 Expectations: Need to introduce policies to provide direct and indirect tax benefits for R&amp;D and investments</a>	We commend the government's efforts to enhance quality healthcare in India and are optimistic about the continued reforms and policies aimed at bolstering innovation and streamlining regulatory processes. We at OPPI look forward to the upcoming Union budget and are hopeful that it will have a positive impact on the healthcare and pharma sector.
19 <sup>th</sup> July	Manipal Hospital Bhubaneswar Launches Adult Immunization Clinic in Partnership with Pfizer Odisha Bhaskar, July 19, 2024	<a href="#">Manipal Hospital Bhubaneswar Launches Adult Immunization Clinic in Partnership with Pfizer</a>	Manipal Hospital, Bhubaneswar, in collaboration with Pfizer Ltd., has launched an Adult Immunization Clinic, marking a significant advancement in the region's healthcare services. This initiative highlights the hospital's commitment to preventive healthcare for adults.



19 <sup>th</sup> July	Sanofi announces expansion of its Global Capacity Center in Hyderabad Express Pharma, July 19, 2024	<a href="#">Sanofi announces expansion of its Global Capacity Center in Hyderabad</a>	Sanofi Healthcare India announced the expansion of its Global Capacity Centre (GCC) in Hyderabad, with plans to invest 400 million over the next six years, with 100 million by 2025. Over the next two years, this GCC (hub) will expand to host up to 2600 employees, making it, reportedly the largest of Sanofi's four global hubs.
19 <sup>th</sup> July	Dr Reddy's inks licensing pact with Takeda to sell gastrointestinal drug The Economic Times, July 19, 2024	<a href="#">Dr Reddy's inks licensing pact with Takeda to sell gastrointestinal drug</a>	Dr Reddy's Laboratories on Thursday said it has inked a licensing pact with Takeda Pharmaceutical Company to commercialise Vonoprazan tablets in India. Vonoprazan is a novel, orally active potassium competitive acid blocker (PCAB), used to treat reflux esophagitis and other acid peptic disorders.
20 <sup>th</sup> July	Budget 2024 Expected To Emphasise PLI Scheme, More Announcements Likely To Promote Manufacturing Jagran, July 20, 2024	<a href="#">Budget 2024 Expected To Emphasise PLI Scheme, More Announcements Likely To Promote Manufacturing</a>	Sudarshan Jain, Secretary-General of the Indian Pharmaceuticals Alliance, emphasises the need for focus on quality and innovation in the upcoming budget. Finance Minister Nirmala Sitharaman has completed the consultation process with all stakeholders before the budget. Anil Matai, Director-General of the Organisation of Pharmaceutical Producers of India, states that these initiatives will help boost R&D and innovation in the industry.
21 <sup>st</sup> July	PTU Centre of Excellence launched at KGH The Hans India, July 21, 2024	<a href="#">PTU Centre of Excellence launched at KGH</a>	The most common reason for women to undergo a hysterectomy in India is heavy menstrual bleeding, said managing director India and country division head South Asia, Bayer's Pharmaceuticals Division Shweta Rai. As part of the 'Preserve the Uterus' nationwide campaign of Bayer's Pharma division, the first Preserve the Uterus (PTU) Centres of Excellence in the state launched at King George Hospital in Visakhapatnam on Saturday.
21 <sup>st</sup> July	Vizag gets country's first CoE for uterus preservation The Times of India, July 21, 2024	<a href="#">Vizag gets country's first CoE for uterus preservation</a>	The second CoE will be launched at Victoria (Ghosha) Hospital in Visakhapatnam. 'Preserve the Uterus' is a nationwide campaign that was launched a few years ago by Bayer's pharma division in collaboration with the Federation of Obstetric and Gynaecological Societies of India (FOGSI).
22 <sup>nd</sup> July	Pharma MNCs seek relief from price control for patented drugs	<a href="#">Pharma MNCs seek relief from price control for patented drugs</a>	The Organisation of Pharmaceutical Producers of India (OPPI), which

	The Economic Times, July 22, 2024		represents prominent multinational pharma companies, has sought exemption for patented and orphan drugs from the government set price controls, people in the know told ET.
22 <sup>nd</sup> July	Bayer Pharma, AP govt & King George Hospital to combat high rates of unnecessary hysterectomies in Vizag BioSpectrum India, July 22, 2024	<a href="#">Bayer Pharma, AP govt &amp; King George Hospital to combat high rates of unnecessary hysterectomies in Vizag</a>	Bayer's Pharmaceuticals division, in collaboration with the Department of Health, Medical and Family Welfare, Government of Andhra Pradesh (AP), inaugurated the first Preserve the Uterus (PTU) Centres of Excellence in the state.
23 <sup>rd</sup> July	-	-	-
24 <sup>th</sup> July	Budget Govt proposes to fully exempt 3 cancer drugs from customs duty The Week, July 24, 2024	<a href="#">Budget Govt proposes to fully exempt 3 cancer drugs from customs duty</a>	Organisation of Pharmaceutical Producers of India (OPPI) Director General Anil Matai said the move will provide much-needed relief to cancer patients by reducing the financial burden of these lifesaving drugs. While we appreciate the positive strides taken in the Union Budget 2024, we were also hoping that the government could announce incentives for pharma companies to develop medications for rare diseases affecting small populations, he added.
24 <sup>th</sup> July	Healthcare sector hopes to stay in the race, benefit from innovation fund The Hindu Business Line, July 24, 2024	<a href="#">Healthcare sector hopes to stay in the race, benefit from innovation fund</a>	Anil Matai, Director General, Organisation of Pharmaceutical Producers of India, pointed to their unmet expectations on incentives to develop medicines for rare diseases affecting small populations. The incentivization of R&D investments in India is necessary as it will be a significant move towards Atma Nirbhar Bharat, and a more resilient and future-ready pharmaceutical industry, he said.
24 <sup>th</sup> July	Budget 2024: Some relief for cancer patients and increased PLI allocation for pharma The Economic Times, July 24, 2024	<a href="#">Budget 2024: Some relief for cancer patients and increased PLI allocation for pharma</a>	The Union Budget 2024 has limited provisions impacting the pharma and healthcare sectors. It has provided relief to cancer patients by fully exempting three more medicines from custom duties. These drugs are Trastuzumab Deruxtecan, Osimertinib and Durvalumab drugs manufactured and sold by AstraZeneca.
24 <sup>th</sup> July	3 cancer drugs now exempt from customs duty; Xray tubes to become cheaper Business Standard, July 24, 2024	<a href="#">3 cancer drugs now exempt from customs duty; Xray tubes to become cheaper</a>	Meanwhile, of the three drugs exempted from customs duty, Trastuzumab Deruxtecan is used for the treatment of breast cancer or gastric or gastroesophageal adenocarcinoma. Fam-Trastuzumab Deruxtecan (Enhertu) injection, produced by AstraZeneca, is

			packaged in 1x1 vials of 100 mg and costs Rs 3,00,000 per piece.
25 <sup>th</sup> July	Union Budget 2024-25 reflects a forward-looking and inclusive approach Express Pharma, July 25, 2024	<a href="#">Union Budget 2024-25 reflects a forward-looking and inclusive approach</a>	We at OPPI commend the government's commitment to improving healthcare access and innovation in India, reflecting a forward-looking approach that aligns with our industry's aspirations. We deeply appreciate the government's decision to exempt three critical cancer medicines Trastuzumab Deruxtecan, Osimertinib, and Durvalumab from customs duties.
25 <sup>th</sup> July	The science of tirzepatide, touted as a game-changing weight loss drug Hindustan Times, July 25, 2024	<a href="#">The science of tirzepatide, touted as a game-changing weight loss drug</a>	The national drug regulation body, Central Drugs Standard Control Organisation (CDSCO), has reportedly authorised the use of the drug, tirzepatide, for treatment of diabetes. The use of tirzepatide for chronic weight management is still under review. The drug is being sold by the pharma company Eli Lilly under the brand names Mounjaro (for diabetes) and Zepbound (for obesity).
26 <sup>th</sup> July	India may have dengue vaccine by 2026; Takeda initiates clinical trials Business Standard, July 26, 2024	<a href="#">India may have dengue vaccine by 2026; Takeda initiates clinical trials</a>	Japanese pharmaceutical company Takeda has also initiated local clinical trials in the country. A Takeda India spokesperson told Business Standard they had received the no-objection certification (NoC) for clinical trials from Indian health authorities.
26 <sup>th</sup> July	GSK'S new campaign educates parents about importance of vaccine for children Exchange 4 Media, July 26, 2024	<a href="#">GSK'S new campaign educates parents about importance of vaccine for children</a>	GSK today announced the launch of its new multichannel campaign 'Ab India Banega 7-Star.' The campaign shows parents that the future of India is in their hands. It encourages them to secure their children's future with 7 essential vaccinations* against 14 diseases, which include chickenpox, hepatitis A, hepatitis B, meningitis, measles, mumps, rubella, pneumonia, influenza, diphtheria, tetanus, pertussis, HiB infection, and polio.
27 <sup>th</sup> July	Budget 2024 a huge disappointment for health sector: Experts, Health News ET Health World, July 27, 2024	<a href="#">Budget 2024 a huge disappointment for health sector: Experts, Health News</a>	The panelist for the session were Anil Matai Director General, The Organization of Pharmaceutical Producers of India (OPPI); Vishal Bali, Executive Chairman, Asia Healthcare Holdings; Anurag Yadav CEO, Gleneagles Healthcare India; Dr SuChin Bajaj, Founder Director.
27 <sup>th</sup> July	SABRE Awards South Asia 2024 Finalists Provoke Media, July 27, 2024	<a href="#">SABRE Awards South Asia 2024 Finalists</a>	The 2024 SABRE Awards South Asia shortlist was selected from among more than 850 entries in this year's competition, which recognizes Superior Achievement in

			Branding, Reputation and Engagement. The campaigns were evaluated by a jury of industry leaders. (OPPI)
27 <sup>th</sup> July	Gujarat Themis Bison Limited Approves Management Changes Market Screener, July 27, 2024	<a href="#">Gujarat Themis Bison Limited Approves Management Changes</a>	Led high performing teams, played key role in five merger & acquisitions, successfully established strategic partnerships, regarded as an industry thought leader, strategic thinker and out of the box problem solver by senior executives. Served as Vice President Organization of Pharmaceutical Producers of India (OPPI), Director General OPPI, Cochair (Pharma Committee) Confederation of Indian Industry (CII).
28 <sup>th</sup> July	-	-	-
29 <sup>th</sup> July	Drug MNCs for keeping patient aid plan out of trade margin formula The Economic Times, July 29, 2024	<a href="#">Drug MNCs for keeping patient aid plan out of trade margin formula</a>	According to the Organisation of Pharmaceutical Producers of India (OPPI), PAP increases access and affordability and putting them under the ambit of TMR will severely impact patients who end up paying more for such products. A lot of multinational companies including Novartis, Roche and AstraZeneca run PAP.
29 <sup>th</sup> July	Novartis Healthcare Gets CDSCO Panel Nod to Study Asciminib Filmcoated Tablets Medical Dialogues, July 29, 2024	<a href="#">Novartis Healthcare Gets CDSCO Panel Nod to Study Asciminib Filmcoated Tablets</a>	Suggesting to add more government sites, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has granted approval to drug major Novartis Healthcare for conducting the Phase IV clinical study of the anti-cancer drug Asciminib film-coated tablets. This came after Novartis Healthcare presented the proposal for the Phase IV clinical trial protocol of Asciminib film-coated tablets (20 mg and 40 mg).
29 <sup>th</sup> July	CDSCO Panel Approves AstraZeneca's Protocol Amendment Proposal to Study anticancer Drug Capivasertib Medical Dialogues, July 29, 2024	<a href="#">CDSCO Panel Approves AstraZeneca's Protocol Amendment Proposal to Study anticancer Drug Capivasertib</a>	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has approved AstraZeneca's protocol amendment proposal to study the anticancer drug Capivasertib. This came after AstraZeneca presented protocol amendment 5, version 6.0 dated 05 March 2024 protocol no. D361DC00001.
29 <sup>th</sup> July	USAID, Takeda Biopharma launch dengue prevention programme across India Business Standard, July 29, 2024	<a href="#">USAID, Takeda Biopharma launch dengue prevention programme across India</a>	The United States Agency for International Development (USAID) and Takeda Biopharmaceuticals India on Friday announced the launch of a dengue prevention campaign titled Haarega Dengue, Haraenge Hum across India.

30 <sup>th</sup> July	Health Talk   To combat dengue menace, a promising vaccine candidate enters phase three trials in India Hindustan Times, July 30, 2024	<a href="#">Health Talk   To combat dengue menace, a promising vaccine candidate enters phase three trials in India</a>	Earlier, in February, this year, Takeda and Biological E. Limited announced a strategic partnership to accelerate progress to make TAK003 a live, attenuated dengue tetravalent vaccine accessible through the Make in India programme.
31 <sup>st</sup> July	Takeda's vaccine Qdenga, a promising solution for dengue control in India: Annapurna Das ET Health World, July 31, 2024	<a href="#">Takeda's vaccine Qdenga, a promising solution for dengue control in India: Annapurna Das</a>	Annapurna Das, General Manager, Takeda Biopharmaceuticals India Pvt Ltd, with 20 years of experience in the pharmaceutical and biotechnology industry across India and Southeast Asia, spoke to ETPharma alongside Dr Sandeep Arora, Head, Medical Affairs & Patient Services, Takeda Biopharmaceuticals India Pvt Ltd.
31 <sup>st</sup> July	GSK's launches new campaign to encourage vaccination among children Express Healthcare, July 31, 2024	<a href="#">GSK's launches new campaign to encourage vaccination among children</a>	GSK has announced the launch of its new multichannel campaign Ab India Banega 7-Star. The campaign encourages the parents to secure their children's future with 7 essential vaccinations* against 14 diseases, which include chickenpox, hepatitis A, hepatitis B, meningitis, measles, mumps, rubella, pneumonia, influenza, diphtheria, tetanus, pertussis, HiB infection, and polio.
31 <sup>st</sup> July	USAID and Takeda launch Dengue prevention campaign Express Healthcare, July 31, 2024	<a href="#">USAID and Takeda launch Dengue prevention campaign</a>	The United States Agency for International Development (USAID) and Takeda Biopharmaceuticals India have launched a new campaign called Haarega Dengue Haraenge Hum (We Will Together Defeat Dengue).

-----